The genetics of scleroderma: Looking into the postgenomic era

Current Opinion in Rheumatology

Volumn 24, Issue 6, 2012, Pages 677-684

  Mayes, Maureen D ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

genetic variants; genome wide association studies; scleroderma; single nucleotide polymorphisms; systemic sclerosis

Indexed keywords

ALPHA INTEGRIN; CD16 ANTIGEN; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERFERON REGULATORY FACTOR 5; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; NOTCH4 RECEPTOR; OX40 LIGAND; PROTEIN; STAT4 PROTEIN; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; COPY NUMBER VARIATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENETICS; HLA SYSTEM; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HLA ANTIGENS; HUMANS; MOLECULAR TARGETED THERAPY; POLYMORPHISM, SINGLE NUCLEOTIDE; SCLERODERMA, SYSTEMIC;

EID: 84866897878     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328358575b     Document Type: Review

References (51)

1. Dieudé P, Wipff J, Guedj M, et al. BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4. Arthritis Rheum 2009; 60:3447-3454.
2. Rueda B, Gourh P, Broen J, et al. BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians. Ann Rheum Dis 2010; 69:700-705.
3. Gourh P, Agarwal SK, Martin E, et al. Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations. J Autoimmun 2010; 34:155-162.
4. Coustet B, Dieudé P, Guedj M, et al. C8orf13-BLK is a genetic risk locus for systemic sclerosis and has additive effects with BANK1: results from a large French cohort and meta-analysis. Arthritis Rheum 2011; 63:2091-2096.
5. Ito I, Kawaguchi Y, Kawasaki A, et al. Association of the FAM167A-BLK region with systemic sclerosis. Arthritis Rheum 2010; 62:890-895.
6. Radstake TR, Gorlova O, Rueda B, et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 2010; 42:426-429.
7. Dieudé P, Boileau C, Guedj M, et al. Independent replication establishes the CD247 gene as a genetic systemic sclerosis susceptibility factor. Ann Rheum Dis 2011; 70:1695-1696.
8. Allanore Y, Saad M, Dieudé P, et al. Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet 2011; 7:e1002091.
9. Martin JE, Broen JC, Carmona FD, et al. Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study followup. Hum Mol Genet 2012; 21:2825-2835.
10. Dieudé P, Bouaziz M, Guedj M, et al. Evidence of the contribution of the X chromosome to systemic sclerosis susceptibility: association with the functional IRAK1196Phe/532Ser haplotype. Arthritis Rheum 2011; 63:3979-3987.
11. Balada E, Simeó n-Aznar CP, Serrano-Acedo S, et al. Lack of association of the PTPN22 gene polymorphism R620W with systemic sclerosis. Clin Exp Rheumatol 2006; 24:321-324. (Pubitemid 44151155)
12. Wipff J, Allanore Y, Kahan A, et al. Lack of association between the protein tyrosine phosphatase nonreceptor 22 (PTPN22)-620W allele and systemic sclerosis in the French Caucasian population. Ann Rheum Dis 2006; 65:1230-1232.
13. Gourh P, Tan FK, Assassi S, et al. Association of the PTPN22 R620W polymorphismwith antitopoisomerase I-and anticentromere antibody-positive systemic sclerosis. Arthritis Rheum 2006; 54:3945-3953. (Pubitemid 44955898)
14. Dieudé P, Guedj M, Wipff J, et al. The PTPN22 620W allele confers susceptibility to systemic sclerosis: findings of a large case-control study of European Caucasians and a meta-analysis. Arthritis Rheum 2008; 58: 2183-2188. (Pubitemid 351988112)
15. Diaz-Gallo LM, Gourh P, Broen J, et al. Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis. Ann Rheum Dis 2011; 70:454-462.
16. Dieudé P, Guedj M, Wipff J, et al. Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian population. Ann Rheum Dis 2010; 69:1958-1964.
17. Koumakis E, Giraud M, Dieudé P, et al. Candidate gene study in systemic sclerosis identifies a rare and functional variant of TNFAIP3 locus as a risk factor for individual polyautoimmunity. Arthritis Rheum 2012; 64:2746-2752.
18. Gourh P, Arnett FC, Tan FK, et al. Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis. Ann Rheum Dis 2010; 69:550-555.
19. Bossini-Castillo L, Broen JC, Simeon CP, et al. A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort. Ann Rheum Dis 2011; 70:638-641.
20. Coustet B, Bouaziz M, Dieudé P, et al. Independent replication and metaanalysis of association studies establish TNFSF4 as a susceptibility gene preferentially associated with the subset of anticentromere-positive patients with systemic sclerosis. J Rheumatol 2012; 39:997-1003.
21. Dieudé P, Guedj M, Wipff J, et al. Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum 2009; 60:225-233.
22. Ito I, Kawaguchi Y, Kawasaki A, et al. Association of a functional polymorphism in the IRF5 region with systemic sclerosis in a Japanese population. Arthritis Rheum 2009; 60:1845-1850.
23. Dieudé P, Dawidowicz K, Guedj M, et al. Phenotype-haplotype correlation of IRF5 in systemic sclerosis: role of 2 haplotypes in disease severity. J Rheumatol 2010; 37:987-992.
24. Carmona FD, Gutala R, Simeó n CP, et al., Spanish Scleroderma Group. Novel identification of the IRF7 region as an anticentromere autoantibody propensity locus in systemic sclerosis. Ann Rheum Dis 2012; 71:114-119.
25. Gorlova O, Martin JE, Rueda B, et al. Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genomewide association strategy. PLoS Genet 2011; 7:e1002178.
26. Broen JC, Bossini-Castillo L, van Bon L, et al., Spanish Systemic Sclerosis Group. A rare polymorphism in the gene for Toll-like receptor 2 is associated with systemic sclerosis phenotype and increases the production of inflammatory mediators. Arthritis Rheum 2012; 64:264-271.
27. Rueda B, Broen J, Simeon C, et al. The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum Mol Genet 2009; 18:2071-2077.
28. Dieudé P, Guedj M, Wipff J, et al. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum 2009; 60:2472-2479.
29. Tsuchiya N, Kawasaki A, Hasegawa M, et al. Association of STAT4 polymorphism with systemic sclerosis in a Japanese population. Ann Rheum Dis 2009; 68:1375-1376.
30. Gourh P, Agarwal SK, Divecha D, et al. Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines. Arthritis Rheum 2009; 60:3794-3806.
31. Martin JE, Carmona FD, Broen JC, et al., Spanish Scleroderma Group. The autoimmune disease-associated IL2RA locus is involved in the clinical manifestations of systemic sclerosis. Genes Immun 2012; 13:191-196.
32. Bossini-Castillo L, Martin JE, Broen J, et al. A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Hum Mol Genet 2012; 21:926-933.
33. Wu SP, Leng L, Feng Z, et al. Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. Arthritis Rheum 2006; 54:3661-3669. (Pubitemid 44737179)
34. Bossini-Castillo L, Simeon CP, Beretta L, et al., Spanish Scleroderma Group. Confirmation of association of the macrophagemigration inhibitory factor gene with systemic sclerosis in a large European population. Rheumatology (Oxford) 2011; 50:1976-1981.
35. Manetti M, Allanore Y, Saad M, et al. Evidence for caveolin-1 as a new susceptibility gene regulating tissue fibrosis in systemic sclerosis. Ann Rheum Dis 2012; 71:1034-1041.
36. Dieudé P, Guedj M, Truchetet ME, et al. Association of the CD226Ser(307) variant with systemic sclerosis: evidence of a contribution of costimulation pathways in systemic sclerosis pathogenesis. Arthritis Rheum2011; 63:1097-1105.
37. Bossini-Castillo L, Simeon CP, Beretta L, et al. A multicentre study confirms CD226 gene association with Systemic Sclerosis-related pulmonary fibrosis. Arthritis Res Ther 2012; 14:R85.
38. McKinney C, Broen JC, Vonk MC, et al. Evidence that deletion at FCGR3B is a risk factor for systemic sclerosis. Genes Immun 2012. doi: 10.1038/gene.2012.15.
39. Carmona FD, Simeon CP, Beretta L, et al. Association of a nonsynonymous functional variant of the ITGAM gene with systemic sclerosis. Ann Rheum Dis 2011; 70:2050-2052.
40. Coustet B, Agarwal SK, Gourh P, et al. Association study of ITGAM, ITGAX, and CD58 autoimmune risk loci in systemic sclerosis: results from 2 large European Caucasian cohorts. J Rheumatol 2011; 38:1033-1038.
41. Skhirtladze C, Distler O, Dees C, et al. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum 2008; 58:1475-1484. (Pubitemid 351705937)
42. Jacob CO, Zhu J, Armstrong DL, et al. Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci USA 2009; 106:6256-6261.
43. Gregersen PK, Olsson LM. Recent advances in the genetics of autoimmune disease. Annu Rev Immunol 2009; 27:363-391.
44. Isaacs A, Lindenmann J. Virus interference. I. the interferon. Proc R Soc Lond B Biol Sci 1957; 147:258-267.
45. Ronnblom L. The type I interferon system in the etiopathogenesis of autoimmune diseases. Ups J Med Sci 2011; 116:227-237.
46. Cho JH, Gregersen PK. Genomics and the multifactorial nature of human autoimmune disease. N Engl J Med 2011; 365:1612-1623.
47. Del Galdo F, Sotgia F, de Almeida CJ, et al. Decreased expression of caveolin-1 in systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum 2008; 58:2854-2865.
48. Gilchrist FC, Bunn C, Foley PJ, et al. Class II HLA associations with autoantibodies in scleroderma: a highly significant role for HLA-DP. Genes Immun 2001; 2:76-81. (Pubitemid 33674232)
49. Zhou X, Lee JE, Arnett FC, et al. HLA-DPB1 and DPB2 are genetic loci for systemic sclerosis: a genome-wide association study in Koreans with replication in North Americans. Arthritis Rheum 2009; 60:3807-3814.
50. Arnett FC, Gourh P, Shete S, et al. Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis 2010; 69:822-827.
51. Kuwana M, Inoko H, Kameda H, et al. Association of human leukocyte antigen class II genes with autoantibody profiles, but not with disease susceptibility in Japanese patients with systemic sclerosis. Intern Med 1999; 38:336-344.